{name}
{subtitle}
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
city
~56 mi. (Morelia, Mexico, +271 more cities)
facility
Local Institution
drug
docetaxel, +2 more drugs
drug type
chemotherapy, +2 more types
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~73 mi. (Santiago de Querétaro, Mexico, +144 more cities)
facility
Cuidados Oncologicos ( Site 0608)
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
city
~73 mi. (Santiago de Querétaro, Mexico, +105 more cities)
facility
Cuidados Oncologicos ( Site 2908)
biomarker
ATM Loss, +62 more biomarkers
condition
Breast Carcinoma, +2 more conditions
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
city
~73 mi. (Santiago de Querétaro, Mexico, +115 more cities)
facility
Cuidados Oncologicos ( Site 3104)
biomarker
ATM Loss, +27 more biomarkers
condition
Breast Carcinoma, +2 more conditions
drug
olaparib, +1 more drug
drug type
immunotherapy, +1 more type